Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.24.2.u1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Operating expenses:        
Research and development $ 1,625,821 $ 1,005,715 $ 3,749,599 $ 4,515,967
General and administrative 1,087,885 1,894,169 2,640,758 3,354,588
Total operating expenses 2,713,706 2,899,884 6,390,357 7,870,555
Loss from operations (2,713,706) (2,899,884) (6,390,357) (7,870,555)
Other income (expense):        
Change in fair value of financial instruments 59,087 606,214 44,954 564,549
Interest expense   (49,182) (76,774) (49,182)
Other income 30,962 30,878 163,432 83,783
Total other income (expense), net 90,049 587,910 131,612 599,150
Net loss (2,623,657) (2,311,974) (6,258,745) (7,271,405)
Other comprehensive loss        
Foreign currency translation adjustment   (171,462)   (175,816)
Comprehensive loss $ (2,623,657) $ (2,483,436) $ (6,258,745) $ (7,447,221)
Net loss per share, basic $ (0.13) $ (0.27) $ (0.32) $ (0.85)
Net loss per share, diluted $ (0.13) $ (0.27) $ (0.32) $ (0.85)
Weighted-average shares outstanding of common shares, basic 19,770,739 8,579,284 19,544,908 8,579,284
Weighted-average shares outstanding of common shares, diluted 19,770,739 8,579,284 19,544,908 8,579,284